BDD Pharma, an Edinburgh, Scotland, UK-based Integrated drug formulation and clinical trials company, raised £2M in funding.
The round was led by existing investors including angel syndicate Archangels, Scottish Enterprise, and new investor British Business Bank.
The company intends to use the funds to accelerate business expansion.
Led by CEO Dr Carol Thomson, BDD is a drug development business, providing pharmaceutical companies with formulation development expertise, on demand GMP manufacture and specialist clinical trial services that combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. It provides onsite CRO and investigative site activities to offer clients a comprehensive integrated solution for conducting early phase clinical trials.
BDD’s patented oral drug delivery technology, OralogiK™, enables the timed release of active pharmaceutical ingredients tailored to specific modified-release needs, including sustained, delayed, multiple pulse, and site-targeted release. OralogiK™ supports the development of novel complex formulations and life cycle management opportunities.
The company also offers, in parallel, formulation development and clinical testing, through BDD SWIFT, which reduces the time from product concept to clinical success.
FinSMEs
16/08/2023